Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» ASCO 2016
ASCO 2016
A Novel, Targeted Drug Yields Promising Results In Stomach And Esophageal Cancer
A Novel, Targeted Drug Yields Promising Results In Stomach And Esophageal Cancer
Forbes
ASCO 2016
Claudiximab
antibodies
Ganymed
stomach cancer
esophageal cancer
Flag link:
AbbVie's Rova-T Update at ASCO: Good or Bad?
AbbVie's Rova-T Update at ASCO: Good or Bad?
Motley Fool
AbbVie
Rova-T
ASCO 2016
small cell lung cancer
Flag link:
Immunomedics' ASCO Letdown
Immunomedics' ASCO Letdown
Motley Fool
ASCO 2016
Immunomedics
Flag link:
Biotech Buzz: ASCO Winners and Losers and Biogen's Discouraging Failure
Biotech Buzz: ASCO Winners and Losers and Biogen's Discouraging Failure
Motley Fool
biotech
ASCO 2016
Biogen
Immunomedics
AbbVie
Juno Therapeutics
Kite Pharma
Flag link:
U.S. regulator says too many drugmakers chasing same cancer strategy
U.S. regulator says too many drugmakers chasing same cancer strategy
Yahoo/Reuters
FDA
oncology
ASCO 2016
Merck
Bristol-Myers Squibb
PD-1 inhibitors
Flag link:
Exelixis, Inc. Gets Some ASCO Love
Exelixis, Inc. Gets Some ASCO Love
Motley Fool
Exelixis
ASCO 2016
Cabometyx
renal cell carcinoma
Flag link:
Johnson & Johnson Courting Huge Revenue Potential In Multiple Myeloma Space
Johnson & Johnson Courting Huge Revenue Potential In Multiple Myeloma Space
Seeking Alpha
JNJ
Multiple Myeloma
daratumumab
ASCO 2016
Flag link:
Biotech Stocks: Much Ado About Nothing at ASCO?
Biotech Stocks: Much Ado About Nothing at ASCO?
Barron's
ASCO 2016
biotech
Celgene
Amgen
Regeneron
Gilead Sciences
Flag link:
Juno Therapeutics leaps on promising clinical data
Juno Therapeutics leaps on promising clinical data
CNBC
Juno Therapeutics
clinical trials
CAR-T
JCAR014
acute lymphoblastic leukemia
ASCO 2016
Flag link:
AbbVie Builds Upon Robust Body of IMBRUVICA® (ibrutinib) Data with Phase 3 Longer-Term Studies in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting
AbbVie Builds Upon Robust Body of IMBRUVICA® (ibrutinib) Data with Phase 3 Longer-Term Studies in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting
Yahoo
AbbVie
Imbruvica
CLL
small lymphocytic lymphoma
ASCO 2016
Flag link:
Why ProNAi Could Be the Biggest Loser at ASCO
Why ProNAi Could Be the Biggest Loser at ASCO
24/7 Wall St
ProNai
ASCO 2016
PNT2258
B-cell lymphoma
Flag link:
Clovis Oncology Presents Data from Phase 2 Studies of Rucaparib in Advanced Ovarian Cancer and Pancreatic Cancer at 2016 ASCO Annual Meeting
Clovis Oncology Presents Data from Phase 2 Studies of Rucaparib in Advanced Ovarian Cancer and Pancreatic Cancer at 2016 ASCO Annual Meeting
Yahoo
Clovis Oncology
rucaparib
ovarian cancer
pancreatic cancer
ASCO 2016
Flag link:
LYNPARZA (olaparib): Latest Data Suggest Potential Overall Survival Advantage in Patients with Platinum Sensitive Ovarian Cancer
LYNPARZA (olaparib): Latest Data Suggest Potential Overall Survival Advantage in Patients with Platinum Sensitive Ovarian Cancer
Yahoo
Lynparza
olaparib
ovarian cancer
AstraZeneca
ASCO 2016
Flag link:
Breast cancer study shows benefit to extended treatment with aromatase inhibitors
Breast cancer study shows benefit to extended treatment with aromatase inhibitors
Stat
breast cancer
ASCO 2016
aromatase inhibitors
Novartis
Femara
Pfizer
Flag link:
Billionaire-backed Ganymed grabs ASCO spotlight with gastric cancer drug
Billionaire-backed Ganymed grabs ASCO spotlight with gastric cancer drug
Fierce Biotech
Ganymed
ASCO 2016
IMAB362
gastric cancer
Flag link:
AbbVie Presents Encouraging Phase 1 Data for Investigational Medicine ABT-414 as Monotherapy in Patients with an Aggressive Brain Cancer at the 2016 American Society of Clinical Oncology Annual Meeting
AbbVie Presents Encouraging Phase 1 Data for Investigational Medicine ABT-414 as Monotherapy in Patients with an Aggressive Brain Cancer at the 2016 American Society of Clinical Oncology Annual Meeting
Yahoo
AbbVie
glioblastoma
brain cancer
ASCO 2016
ABT-414
Flag link:
J&J myeloma drug, in combo regimen, delays worsening of the disease
J&J myeloma drug, in combo regimen, delays worsening of the disease
Yahoo/Reuters
JNJ
Multiple Myeloma
Darzalex
Takeda
Velcade
ASCO 2016
Flag link:
Exelixis and its partner Ipsen announce phase 3 trial results of CABOMETYX™ (cabozantinib) tablets demonstrating significant overall survival benefit for previously treated patients with advanced renal cell carcinoma presented at ASCO
Exelixis and its partner Ipsen announce phase 3 trial results of CABOMETYX™ (cabozantinib) tablets demonstrating significant overall survival benefit for previously treated patients with advanced renal cell carcinoma presented at ASCO
Yahoo
Exelixix
Ipsen
clinical trials
advanced renal cell carcinoma
Cabometyx
ASCO 2016
Flag link:
New Data for KEYTRUDA® (pembrolizumab) in Combination with Talimogene Laherparepvec, Dabrafenib Plus Trametinib, or Low-Dose Ipilimumab in Advanced Melanoma Presented at 2016 ASCO Annual Meeting
New Data for KEYTRUDA® (pembrolizumab) in Combination with Talimogene Laherparepvec, Dabrafenib Plus Trametinib, or Low-Dose Ipilimumab in Advanced Melanoma Presented at 2016 ASCO Annual Meeting
Yahoo
Keytruda
Merck
ASCO 2016
melanoma
Flag link:
New Roche med Tecentriq shines in study of untreated bladder cancer patients
New Roche med Tecentriq shines in study of untreated bladder cancer patients
Fierce Pharma
Roche
Tecentriq
bladder cancer
ASCO 2016
Flag link:
Pages
1
2
next ›
last »